AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15589864
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg anastrozole
Trial: 15589864
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg anastrozole
Trial: 15589864
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg anastrozole
Trial: 15589864
Drug: five daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: five daily doses of 10 mg or 15 mg anastrozole
Trial: 12359281
Drug: IV 0.1
RxNorm normalized name: Immphentiv 0.1 MG/ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV 0.1 mg/Kg chlorpromazine (CPZ)
Trial: 22379743
Drug: Dexpanthenol nasal
RxNorm normalized name: Dexpanthenol
DrugBank: Dexpanthenol (DB09357)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dexpanthenol nasal spray
Trial: 335490
Drug: Cimetidine 1
RxNorm normalized name: cimetidine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 1 g daily for four weeks
Trial: 335490
Drug: Inactive tablets
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive tablets (control)
Trial: 31278094
Drug: 1000 mg/day
RxNorm normalized name: RibaTab 1000 MG/day Compliance Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg/day trans-resveratrol for 8 weeks
Trial: 28638702
Drug: 10 mg/day
RxNorm normalized name: Adlarity 10 MG/Day Weekly Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/day Rosuvastatin
Trial: 28638702
Drug: 20 mg/day
RxNorm normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/day Rosuvastatin
Trial: 11491417
Drug: Zidovudine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zidovudine (300 mg twice per day) plus Lamivudine (150 mg twice per day) plus Nelfinavir placebo (three times per day)
Trial: 11491417
Drug: Zidovudine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zidovudine (300 mg twice per day) plus Lamivudine (150 mg twice per day) plus Nelfinavir (750 mg three times per day)
Trial: 11491417
Drug: Zidovudine/lamivudine/nelfinavir (after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zidovudine/lamivudine/nelfinavir (after switching from double nucleoside therapy)
Trial: 11491417
Drug: Zidovudine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zidovudine (300 mg twice per day) plus Lamivudine (150 mg twice per day)
Trial: 29987421
Drug: Endovascular treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular treatment (EVT) after adjustment for FIV
Trial: 23664040
Drug: Light emitting
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Light emitting diode therapy (LEDT)
Trial: 21859685
Drug: Ofatumumab 700
RxNorm normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ofatumumab 700 mg (two infusions, 2 weeks apart)
Trial: 17610057
Drug: Tomatis Method
RxNorm normalized name: Tomato
DrugBank: Tomato (DB10573)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tomatis Method (Treatment)
Trial: 16859505
Drug: Recombinant activated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant activated factor VII (rFVIIa) at an initial dose of 200 microg x kg‐1 after transfusion of eight red blood cell units, followed by additional doses of 100 microg x kg‐1, one and three hours later
Trial: 11193130
Drug: Continued medication
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continued medication group (C), n = 24
Trial: 8473466
Drug: D‐Trp6 LHRH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D‐Trp6 LHRH microcapsules (i.m. injection) at 2 months and 1 month prior to surgery
Trial: 8473466
Drug: No pre‐operative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No pre‐operative treatment (control group)
Trial: 3964516
Drug: Sublingual buprenorphine
RxNorm normalized name: buprenorphine Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual buprenorphine (0.2 mg)
Trial: 3964516
Drug: Intramuscular buprenorphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular buprenorphine (0.15 mg)
Trial: 3964516
Drug: Both routes
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both routes (sublingual and i.m.)
Trial: 8138651
Drug: Intramuscular buprenorphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular buprenorphine
Trial: 28093466
Drug: Sacubitril/valsartan 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sacubitril/valsartan 200 mg
Trial: 20015788
Drug: Oral levofloxacin
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral levofloxacin (LVFX)
Trial: 20015788
Drug: Intravenous flomoxef
RxNorm normalized name: flomoxef
DrugBank: Flomoxef (DB11935)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous flomoxef (FMOX)
Trial: 7607735
Drug: Methacholine (nonselective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methacholine (nonselective agonist)
Trial: 7607735
Drug: Atropine (nonselective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine (nonselective antagonist)
Trial: 7607735
Drug: Pirenzepine (M1-selective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirenzepine (M1-selective antagonist)
Trial: 7607735
Drug: AF-DX 116
RxNorm normalized name: Canesten AF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AF-DX 116 (M2-selective antagonist)
Trial: 627337
Drug: Indomethacin 3
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indomethacin 3 X 25 mg orally for 5 days starting 2 days before menstruation
Trial: 23446090
Drug: Liposome bupivacaine
RxNorm normalized name: bupivacaine liposome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposome bupivacaine (66 to 532 mg)
Trial: 23446090
Drug: Bupivacaine HCl
RxNorm normalized name: bupivacaine HCl
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupivacaine HCl (75 to 200 mg)
Trial: 20854436
Drug: Tomato paste
RxNorm normalized name: Tomato
DrugBank: Tomato (DB10573)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tomato paste (55 g daily, 16 mg lycopene)
Trial: 17185999
Drug: Buprenorphine (0.05‐0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine (0.05‐0.6 mg/70 kg)
Trial: 17185999
Drug: Fentanyl (0.075‐0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (0.075‐0.5 mg/70 kg)
Trial: 9308614
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg of lamotrigine 1 hour before spinal anesthesia
Trial: 3555028
Drug: 750 mg
RxNorm normalized name: bran 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 mg of ciprofloxacin orally every 12 hours for two weeks
Trial: 3555028
Drug: 1,000 mg
RxNorm normalized name: bran 1,000 mg ORAL WAFER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,000 mg of ciprofloxacin orally every 12 hours for two weeks
Trial: 27218285
Drug: Pimpinella anisum‐based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pimpinella anisum‐based herbal medicine (Sinupim), 2 drops in each nostril every 12 hours for 4 weeks
Trial: 27218285
Drug: Fluticasone nasal
RxNorm normalized name: fluticasone nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone nasal spray, 2 puffs in each nostril every 12 hours for 4 weeks
Trial: 24691094
Drug: Evolocumab 140
RxNorm normalized name: evolocumab 140 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evolocumab 140 mg biweekly
Trial: 21166990
Drug: Mandibular two-implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mandibular two-implant overdentures with different attachment systems
Trial: 12956494
Drug: Mandibular two-implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mandibular two-implant overdentures
Trial: 17095130
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of hepatitis B vaccine
Trial: 17095130
Drug: Three doses
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three doses of hepatitis B vaccine
Trial: 16298778
Drug: Fluoxetine and
RxNorm normalized name: fluoxetine and psycholeptics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine and placebo light treatment
Trial: 16298778
Drug: Light treatment
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Light treatment and placebo pill
Trial: 11991015
Drug: Shellyquine (plain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shellyquine (plain formulation)
Trial: 11991015
Drug: Dawaquin (sugar-coated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dawaquin (sugar-coated formulation)
Trial: 2339797
Drug: Epidural injection
RxNorm normalized name: Sufentanil Citrate 50 ug in 1 mL EPIDURAL INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural injection of warm lidocaine (40.6 +/‐ 0.7 degrees C)
Trial: 2339797
Drug: Epidural injection
RxNorm normalized name: Sufentanil Citrate 50 ug in 1 mL EPIDURAL INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural injection of cold lidocaine (16.0 +/‐ 4.7 degrees C)
Trial: 26109120
Drug: High flow
RxNorm normalized name: Blood Set High Flow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High flow (HF) therapy
Trial: 23689263
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg Zn as zinc sulfate, daily for 21 days
Trial: 23689263
Drug: Placebo, daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, daily for 21 days
Trial: 19159453
Drug: Aspirin and
RxNorm normalized name: Aspirin and Caffeine Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin and Omega-3 fatty acids
Trial: 19159453
Drug: Placebo (Aspirin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (Aspirin)
Trial: 19159453
Drug: Aspirin and
RxNorm normalized name: Aspirin and Caffeine Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin and Omega-3 fatty acids placebo
Trial: 19159453
Drug: Aspirin placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin placebo and Omega-3 fatty acids
Trial: 17653751
Drug: triamcinolone (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: triamcinolone (4 mg) injection
Trial: 9772056
Drug: Modified triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified triple therapy (PCM): 40 mg pantoprazole b.i.d., 500 mg clarithromycin t.i.d., and 500 mg metronidazole t.i.d. for 7 days; followed by 40 mg pantoprazole o.d. until day 28.
Trial: 9772056
Drug: Dual therapy
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual therapy (PC): 40 mg pantoprazole b.i.d. and 500 mg clarithromycin t.i.d. for 14 days; followed by 40 mg pantoprazole o.d. until day 28.
Trial: 3973786
Drug: Short-term prophylaxis
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term prophylaxis with rectally administered diazepam for 18 months, mean of five doses per child per year
Trial: 3973786
Drug: Short-term prophylaxis
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term prophylaxis with rectally administered diazepam for 18 months
Trial: 29912425
Drug: SCFP at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCFP at 14 g·steer‐1·d‐1
Trial: 29912425
Drug: SCFP at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCFP at 0 g·steer‐1·d‐1 (Control)
Trial: 29912425
Drug: SCFP at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCFP at 28 g·steer‐1·d‐1
Trial: 25787121
Drug: 1% metformin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% metformin gel with scaling and root planing (SRP)
Trial: 25201648
Drug: Feeling Better
RxNorm normalized name: BITTER ORANGE PEEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Feeling Better intervention (Cognitive Behavioural Therapy programme)
Trial: 21911258
Drug: Adjunctive oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive oral S-adenosylmethionine (SAMe)
Trial: 15061293
Drug: 0.2 mg
RxNorm normalized name: niacin 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg oral ramosetron
Trial: 15061293
Drug: 0.3 mg
RxNorm normalized name: biotin 0.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg intravenous ramosetron
Trial: 24152567
Drug: Cilostazol 100
RxNorm normalized name: cilostazol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilostazol 100 mg twice daily (Triple)
Trial: 24152567
Drug: Clopidogrel 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 150 mg daily (Double)
Trial: 17377212
Drug: Simvastatin 40
RxNorm normalized name: simvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 40 mg/day within 24 hours after stroke onset (Group I, n = 18)
Trial: 14687744
Drug: Conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated equine estrogens 0.625 mg combined with medroxyprogesterone acetate 5 mg (CEE/MPA, n=31)
Trial: 14687744
Drug: Tibolone 2.5
RxNorm normalized name: tibolone 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tibolone 2.5 mg (n=42)
Trial: 8483562
Drug: MMM (mitomycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMM (mitomycin 7‐8 mg/m2 i.v. every 6 weeks; mitoxantrone 7‐8 mg/m2 i.v. every 3 weeks; methotrexate 35 mg/m2 i.v. every 3 weeks)
Trial: 8483562
Drug: VAC (vincristine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VAC (vincristine 1.4 mg/m2 every 3 weeks, anthracycline 30 mg/m2 every 3 weeks, cyclophosphamide 400 mg/m2 every 3 weeks)
Trial: 8483562
Drug: CMF (cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMF (cyclophosphamide 100 mg orally, days 1‐14; methotrexate 35 mg/m2 i.v. days 1 and 8; 5‐fluorouracil 1 g i.v. days 1 and 8)
Trial: 30067323
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of botulinum toxin A
Trial: 21040375
Drug: Racemic ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Racemic ketamine (3 mg kg(‐1))
Trial: 21040375
Drug: S-ketamine (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-ketamine (1.5 mg kg(‐1))
Trial: 323025
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg physostigmine i.v.
Trial: 19299903
Drug: UFT in
RxNorm normalized name: UFT
DrugBank: Tegafur-uracil (DB09327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFT in combination with oxaliplatin (TEGAFOX)
Trial: 19299903
Drug: UFT in
RxNorm normalized name: UFT
DrugBank: Tegafur-uracil (DB09327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFT in combination with irinotecan (TEGAFIRI)
Trial: 14962401
Drug: Invalid preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Invalid preparation for the irrelevant task
Trial: 14962401
Drug: Invalid preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Invalid preparation
Trial: 3887870
Drug: PPC (amino
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPC (amino acid preparation)
Trial: 25592006
Drug: Green coffee
RxNorm normalized name: Green coffee bean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green coffee bean extract (10 mg/kg, 5 mg/kg chlorogenic acid)
Trial: 23503735
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (bronchodilators, antibiotics, oxygen, patient education)
Trial: 18263663
Drug: Varenicline (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varenicline (1 mg twice daily for 12 weeks)
Trial: 18263663
Drug: Transdermal NRT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal NRT (21 mg/day reducing to 7 mg/day for 10 weeks)
Trial: 18263663
Drug: Transdermal NRT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal NRT
Trial: 16426449
Drug: Active Physical
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active Physical Treatment (APT)
Trial: 16426449
Drug: Combined Treatment
RxNorm normalized name: POISON IVY/OAK/SUMAC EXTRACTS COMBINED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined Treatment (CT) of APT and CBT
Trial: 12483414
Drug: N‐[(11)C‐methyl]‐L‐deuterodeprenyl (DED)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N‐[(11)C‐methyl]‐L‐deuterodeprenyl (DED) imaging
Trial: 1468186
Drug: ponalrestat 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ponalrestat 600 mg/day
Trial: 29463231
Drug: Immunosuppressive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunosuppressive therapy adherence assessment
Trial: 28606219
Drug: Dietary calcium
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dietary calcium intake (mean 870 mg/d)
Trial: 26206258
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with anthracyclines (epirubicin -> cyclophosphamide, methotrexate and fluorouracil (CMF))
Trial: 26206258
Drug: Chemotherapy without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chemotherapy without anthracyclines (CMF)
Trial: 21441356
Drug: High concurrent
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High concurrent self-regulatory efficacy (SRE) group
Trial: 21441356
Drug: Low concurrent
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low concurrent self-regulatory efficacy (SRE) group
Trial: 17335643
Drug: rTMS treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rTMS treatment with reduced frequency (from two sessions per day to one)
Trial: 17335643
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for TEM (decrease or discontinuation of antidepressant and/or rTMS treatment and/or use of anti-manic medication)
Trial: 16996855
Drug: 32 mg
RxNorm normalized name: caffeine 32 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 32 mg candesartan cilexetil
Trial: 12790064
Drug: Standard-of-care treatments
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-of-care treatments for postoperative pain management
Trial: 8732473
Drug: Menorest (transdermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Menorest (transdermal oestradiol) at doses of 50, 75, 100 micrograms/day in study 201 and 25, 50, 75 micrograms/day in study 305, administered cyclic sequential or continuous sequential with dydrogesterone 20 mg/day during the last 14 days.
Trial: 8732473
Drug: Menorest (transdermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Menorest (transdermal oestradiol)
Trial: 1426355
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid 200 mg/d
Trial: 1426355
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid 1000 mg/d
Trial: 6697071
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg Depomedrone in normal saline made up to 20 ml
Trial: 6697071
Drug: 20 ml
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 ml 0.25% bupivacaine solution
Trial: 6697071
Drug: Needling with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Needling with a standard Touhy injection needle into the interspinous ligament (no injection)
Trial: 28166785
Drug: Initial DMARD-monotherapy
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial DMARD-monotherapy (sulfasalazine (SSZ) or methotrexate (MTX))
Trial: 28166785
Drug: Initial combination
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial combination MTX/etanercept
Trial: 28166785
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (Initial DMARD-monotherapy and Initial MTX / prednisolone-bridging)
Trial: 25476268
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received a leaflet on preparation instructions
Trial: 21355003
Drug: Trastuzumab (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab (8 mg/kg loading dose, 6 mg/kg every 3 weeks for 1 year) plus chemotherapy
Trial: 21355003
Drug: Trastuzumab (with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab (with chemotherapy)
Trial: 11758296
Drug: Various treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various treatment options for functional dyspepsia
Trial: 9532994
Drug: Oral metronidazole
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral metronidazole treatment during pregnancy
Trial: 2023417
Drug: Methotrexate 50
RxNorm normalized name: methotrexate 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate 50 mg/m2 on the 3rd, 10th, and 17th postoperative days